51.65
-1.52 (-2.86%)
| Previous Close | 53.17 |
| Volume | 2,711,974 |
| Price / Sales | 63.97 |
| 52 Weeks Range |
| Operating Margin (TTM) | -9,856.30% |
| Diluted EPS (TTM) | -5.29 |
| Quarterly Revenue Growth (YOY) | 89.10% |
| Total Debt/Equity (MRQ) | 727.94% |
| Current Ratio (MRQ) | 5.99 |
| Operating Cash Flow (TTM) | -398.00 M |
| Levered Free Cash Flow (TTM) | -241.41 M |
| Return on Assets (TTM) | -34.12% |
News Mood
-
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
5 days ago, 3:12AM
-
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
6 days ago, 3:00AM
-
Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market
6 days ago, 2:12AM
AIStockmoo Score
| Value 30% | -4.0 |
| Earns below its cost of capital. Returns on capital falling. info | |
| High debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -3.0 |
| No clear trend over the past year. Far below its 52-week high. info | |
| In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. Volume is heavier on down days. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.6 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 1.7 |
| Insiders net selling recently. info | |
| Institutions net +5.94% of shares in their latest 13F filings: 289 holders increased, 202 decreased (quarter to 30 Sep 2026). info | |
| Short interest +2.8% from 31 Aug to 30 Oct 2026, 14.2 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Earnings per share have mostly fallen. Made a loss in recent years. info | |
| Below its medium-term trend line. info | |
| Price is low against its 52-week average. Up over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Levels trending down. info | |
| Final Score | -1.96 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cytokinetics, Incorporated | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| CYTK | - | - | - | - | -2.0 |
| SYRE | 9 B | - | - | 10.08 | 1.1 |
| MDGL | 9 B | - | - | 14.74 | -0.4 |
| CORT | 7 B | - | 47.78 | 8.89 | -1.5 |
| DFTX | 5 B | - | - | 4.54 | 0.0 |
| FOLD | 5 B | - | - | - | 0.0 |
Select this tab to load the latest available analysis.
|
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.72% |
| % Held by Institutions | 119.58% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| PARSHALL B LYNNE | - | 55.14 | -5,000 | -275,700 |
| Aggregate Net Quantity | -5,000 | |||
| Aggregate Net Value ($) | -275,700 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 55.14 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| PARSHALL B LYNNE | Director | 09 Nov 2026 | Sell (-) | 5,000 | 55.14 | 275,700 |
Institutions
Institutional ownership: 130.63%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 289 | 25,992,791 |
| Decreased | 202 | 16,120,658 |
| New | 66 | 3,317,551 |
| Sold out | 68 | 4,939,593 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 17,929,635 | 14.2 |
| 15 Oct 2026 | 18,628,116 | 8.7 |
| 30 Sep 2026 | 19,333,243 | 8.4 |
| 15 Sep 2026 | 17,481,383 | 10.5 |
| 31 Aug 2026 | 17,442,378 | 9.7 |
| 14 Aug 2026 | 16,323,712 | 7.7 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
Cytokinetics (NASDAQ:CYTK) executives said the company is seeing momentum in the launch of heart drug MYQORZO and is preparing to seek U.S. approval for its use in a second form of hypertrophic cardiomyopathy. Speaking at the UBS Biopharma Conference, President and CEO Robert Blum also announced th… |
| 16 Nov 2026 | Yahoo Finance |
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 13, 2026 it granted stock options to purchase an aggregate of 64,110 shares of common stock and 42,496 restricted stock units (RSUs) that will be settled in… |
| 16 Nov 2026 | Yahoo Finance |
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker Metoprolol SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration… |
| 16 Nov 2026 | Yahoo Finance |
Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Market
Cytokinetics (NASDAQ:CYTK) executives said the launch of its heart drug MYQORZO is gaining prescribers and market share as the company prepares regulatory submissions that could expand use of aficamten, the drug’s active ingredient. Chief Business Officer Isaac Ciechanover said revenue rose 76% fro… |
| 09 Nov 2026 | Yahoo Finance |
Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
New Analyses Across Obstructive and Non-obstructive HCM Expand Clinical Evidence for Aficamten SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data related to aficamten were presented at the Hypertrophic… |
| 09 Nov 2026 | Yahoo Finance |
FDA Decision Watch: Summit’s Lung Cancer Drug, Cytokinetics’ Heart Therapy And Teva’s Igalmi In Spotlight This Week
The FDA is set to announce its verdict on three closely watched therapies this week, ahead of a busy month which includes a decision on Capricor Therapeutics’ Deramiocel. |
| 05 Nov 2026 | Yahoo Finance |
Cytokinetics' Myqorzo Could Inflect Revenue Starting 2027, RBC Capital Markets Says
Cytokinetics' (CYTK) Myqorzo could inflect revenue in 2027 and beyond given its positive launch tra… |
| 05 Nov 2026 | Yahoo Finance |
Cytokinetics (CYTK) Q3 2026 Earnings Call Transcript
MYQORZO sales climbed sharply as prescriber adoption broadened beyond specialists. |
| 05 Nov 2026 | Yahoo Finance |
Cytokinetics, Incorporated Q3 2026 Earnings Call Summary
Moby summary of Cytokinetics, Incorporated's Q3 2026 earnings call… |
| 05 Nov 2026 | Yahoo Finance |
Cytokinetics (CYTK) Could Be 41% Undervalued Following Strong Q3 And Aficamten Data
Cytokinetics (CYTK) is back in focus after its third quarter update, with revenue of US$47.56 million, a narrower loss, and fresh late stage data for heart drug aficamten adding to the MYQORZO story. The third quarter update has arrived after a choppy stretch for Cytokinetics, with the share price… |
| 05 Nov 2026 | Yahoo Finance |
How MYQORZO Adoption Will Impact Cytokinetics (CYTK) Stock
Cytokinetics reported third quarter 2026 revenue of US$47.56 million versus US$1.94 million a year earlier, with the quarterly net loss narrowing to US$190.07 million and loss per share from continuing operations at US$1.37. Commercial uptake of heart drug MYQORZO and progress toward expanded use… |
| 05 Nov 2026 | Yahoo Finance |
Cytokinetics Inc (CYTK) (Q3 2026) Earnings Call Highlights: Micorzo Launch Surges with 76% ...
Cytokinetics Inc (CYTK) posts $47.6 million in Q3 2026 revenue as Micorzo demand accelerates, prescriber base nears 1,100, and Acacia HCM data bolster the pipeline. |
| 04 Nov 2026 | Yahoo Finance |
Cytokinetics Q3 Earnings Call Highlights
Cytokinetics (NASDAQ:CYTK) reported $44.5 million in third-quarter net revenue from heart drug MYQORZO, up 76% from the prior quarter, as the company prepares regulatory submissions that could expand the treatment’s use. President and CEO Robert Blum said the launch, nearly nine months in, continue… |
| 04 Nov 2026 | Yahoo Finance |
Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of +8.67% and +10.57%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 04 Nov 2026 | Yahoo Finance |
Cytokinetics: Q3 Earnings Snapshot
(AP) — SOUTH SAN FRANCISCO, Calif. (CYTK) on Wednesday reported a loss of $190… |
| 04 Nov 2026 | Yahoo Finance |
Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update
MYQORZO® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 ~$1.6 Billion in Cash, Cash Equivalents and Investments as of September 30, 2026 SOUTH SAN FRANCISCO… |
| 03 Nov 2026 | Yahoo Finance |
Cytokinetics to Participate in November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in November: Stifel 2026 Healthcare Conference: Fireside chat on Tuesday… |
| 02 Nov 2026 | Yahoo Finance |
Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three upcoming presentations, including two Late Breaking Oral Abstract presentations and one poster presentation, at the Hypertrophic Cardiomyopathy Medical Society Scientific… |
| 29 Oct 2026 | Yahoo Finance |
Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 28 Oct 2026 | Yahoo Finance |
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 21 Oct 2026 | Yahoo Finance |
Cytokinetics to Announce Third Quarter Results on November 4, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a… |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |